Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.

The company said it has also granted the underwriters of the offering the option to buy an additional 1.7 million shares at the $4 offering price. If exercised, the option would boost the value of the IPO to $51.75 million.

The company anticipates going public this week under the symbol “RGLS.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.